Bold claim: AI-powered liquid biopsies could revolutionize cancer screening with painless tests that detect exosomes in blood or urine, offering early, non-invasive insight into tumor biology. And this is where it gets more intriguing: researchers see a future where a simple drop of blood might reveal cancer biomarkers long before symptoms appear, guiding timely intervention and personalized treatment.
A comprehensive literature review underpins this outlook. Led by Mohammad Harb Semreen, Professor of Pharmaceutical Chemistry at the University of Sharjah, the study synthesizes evidence from over 100 investigations published between 2018 and 2025 and appears in Clinica Chimica Acta. It identifies four key associations and provides interpretive analysis and expert perspectives to clarify how exosomes—tiny vesicles shed by nearly all cells—mirror cellular changes occurring in cancer.
Exosomes carry a molecular cargo that can include proteins, nucleic acids, lipids, and metabolites. In cancer, this cargo changes in ways that reflect tumor activity. By applying a multi-omics approach—proteomics, transcriptomics, metabolomics, and lipidomics—scientists can map how cancers communicate, grow, and resist treatment. This could yield precise, reliable biomarkers that enable earlier cancer detection, prognosis of aggressiveness, and real-time monitoring of treatment responses.
Exosomes circulate in body fluids and can serve as non-invasive indicators of cancer. Advances in artificial intelligence are accelerating this effort by sifting through vast molecular datasets to detect patterns invisible to human analysis, enabling faster and more accurate biomarker discovery.
Semreen emphasizes the practical appeal: exosomes can be obtained from simple fluids like blood or urine, paving the way for a liquid biopsy that could replace more invasive tissue sampling in some scenarios. Beyond passive markers, exosomes actively influence tumor spread, immune evasion, and drug resistance, underscoring their role as both messengers and manipulators in cancer biology.
The paper argues that integrating multi-omics data with AI can reveal clinically meaningful signals from these vesicles, bringing us closer to truly personalized and predictive cancer diagnostics. A routine blood test could someday disclose the earliest signs of cancer and inform treatment choices with unprecedented precision.
With cancer remaining a leading global killer, the review highlights the potential of AI-assisted blood or urine tests to detect disease quickly and non-invasively, enabling early intervention and improved outcomes.
Statistics from the International Agency for Research on Cancer (IARC) illustrate the scale of the challenge: around 20 million new cancer cases and nearly 10 million deaths in 2022, with about 53.5 million people living within five years of a cancer diagnosis. The lifetime risk of developing cancer is roughly 1 in 5, with mortality slightly higher for men than women.
Lead author Fatima Maher Al-Daffaie, a PhD candidate at the University of Sharjah, notes that exosomes carry cancer cells’ whispers and that decoding them could allow earlier, smarter treatment. The goal is to transform a simple blood test into a robust diagnostic tool that provides a real-time view of tumor biology, potentially reducing the need for invasive procedures.
Practically, the researchers see immediate applications in developing liquid biopsies that analyze exosome cargo to detect cancer at earliest stages, monitor how tumors respond to therapy, and even anticipate relapse before symptoms appear. Since exosomes reflect their parent tumors’ molecular fingerprints, they offer a non-invasive, time-sensitive snapshot of disease activity that could enable doctors to track cancer over time more safely and repeatedly than traditional tissue biopsies.
Another promising angle involves using exosomes as delivery vehicles for cancer therapies. These natural nanoscale carriers can be engineered to ferry chemotherapy drugs, RNA-based therapies, or gene-editing tools directly to tumor sites, potentially increasing efficacy while reducing side effects due to their compatibility with the human body.
Associate Professor Ahmad Abuhelwa highlights the broader implication: studying exosome signatures could tailor treatments to individual patients and track how each tumor evolves, moving precision oncology from theory to everyday clinical practice.
While formal industry collaborations are not yet in place, the field is drawing major international interest. Exosome-based diagnostics and liquid biopsies are among the fastest-growing areas in precision medicine, attracting substantial investment from biotech and pharmaceutical sectors. The researchers anticipate partnerships with companies and research institutions focused on next-generation cancer diagnostics and personalized monitoring tools as the work progresses.
